Loading stock data…
MANE
$101.00+2.00 (+2.02%)
Market ClosedLast close May 1
Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$101.00
Potential Upside
5%
Whystock Fair Value$106.05
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus3 analysts
Mean target$116.00+14.9%
Range$90.00 – $138.00
Fundamentals
Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's p...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.59B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
22.73%
Volume
Today's trading volume
995,538
Recent News
Veradermics (MANE) Reports Positive Phase 2/3 Results for Male Pattern Hair Loss Treatment VDPHL01
Veradermics Incorporated (NYSE:MANE) is one of the small-cap stocks that are on fire right now. On April 27, Veradermics announced positive topline results from its Phase 2/3 “302” clinical trial evaluating VDPHL01, a proprietary extended-release oral minoxidil formulation for male pattern hair loss. The study, which included 519 participants, met all primary and key secondary […]
Newly Listed Veradermics Hair Loss Drug Shows Hair Growth Gains
Veradermics Inc. announced on Monday that its novel oral formulation, VDPHL01, achieved positive results in a Phase 2/3 trial for pattern hair loss. Hair Growth Gains And Patient Response Metrics The development positions the treatment as a potential first FDA-approved oral pill for hair loss in nearly 30 years. Hair Growth Increase: 30.3 hairs/cm² (once daily) and 33.0 hairs/cm² (twice daily) compared to 7.3 hairs/cm² for placebo. Patient Improvement: 79.3% (once daily) and 86.0% (twice daily)
Midday Fly By: Verizon reports ‘beat and raise,’ Shell to acquire ARC
The major averages were broadly lower amid stalled peace negotiations between the U.S. and Iran as well as new escalation in the Strait of Hormuz. Investors are also balancing continued strength in corporate earnings and AI-driven optimism with rising geopolitical tension and macro uncertainty. Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart I
Biotech Skyrockets Nearly 50% On A Potential Game-Changer In Hair Loss
Veradermics' oral version of Rogaine led to "rapid and robust hair growth" for men with pattern hair loss. The recent IPO stock surged.
Veradermics Shares Jump 17% on Promising Hair Loss Trial Results
Veradermics Incorporated (NYSE:MANE) saw its stock rise 17% on Monday after announcing positive topline data from a Phase 2/3 clinical study of its oral hair loss treatment, VDPHL01. The trial, known as Study ’302’, included 519 participants and successfully met all primary and key secondary endpoints with statistical significance.